The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

There is a critical need for the development of novel treatments for nicotine dependence.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

This was a secondary data analysis of 3 randomized clinical trials: a placebo-controlled trial of transdermal nicotine (N = 545); an open-label nicotine replacement therapy (patch vs spray) trial (N = 566); and a bupropion placebo-controlled trial (N = 538).

In separate logistic regression models, the maximum number of consecutive days of abstinence during the first week after the TQD was used to predict biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT) and 6 months post-TQD.

How the Study Was Run

The design is described as randomized, open-label and placebo-controlled.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

PubMed files the paper under topics including Bupropion, Nicotine, Recurrence, Smoking Cessation, Substance Withdrawal Syndrome, Tobacco Use Cessation Devices and Tobacco Use Disorder.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Journal of addiction medicine), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.